Physician profile
Thomas J Cunningham
NPI 1982191136
$4,143.02
in general payments reported to CMS, 2019-2025
28 companies · $1,596 in 2025
The $1,596 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.87 · 2022: $246 · 2023: $1,006 · 2024: $1,283 · 2025: $1,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,871 · Entertainment: $13.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,871.44 |
| Entertainment | $13.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $607.47 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $422.87 | 2022-2025 | |
| Amgen INC. | $344.82 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Abbott Laboratories | $326.50 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $302.74 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $301.95 | 2022-2025 | |
| Dexcom, INC. | $260.52 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $254.43 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $167.57 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $159.11 | 2022-2025 | Vraylar, Ubrelvy |
| Corcept Therapeutics | $148.60 | 2024-2025 | Korlym |
| Glaxosmithkline, LLC. | $148.13 | 2022-2024 | Trelegy Ellipta, Shingrix |
| Phathom Pharmaceuticals, INC. | $144.94 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.70 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.82 | 2022-2024 | Ofev |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $65.25 | 2023-2025 | Accrufer |
| Axsome Therapeutics, INC. | $54.57 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $37.23 | 2025 | Capvaxive, Gardasil 9 |
| Pulmonx Corporation | $30.89 | 2023 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter |
| Otsuka America Pharmaceutical, INC. | $23.43 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $21.03 | 2024 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $17.96 | 2025 | Gemtesa |
| Boston Scientific Corporation | $17.82 | 2023 | Wavewriter Alpha Prime 16 |
| Antares Pharma, INC. | $15.08 | 2025 | Xyosted |
| Tolmar, INC. | $14.05 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.02 | 2023 | Quviviq |
| Optos, INC. | $13.65 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Janssen Pharmaceuticals, INC | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.